Brown Advisory’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.6M | Buy |
7,541
+356
| +5% | +$69.9K | ﹤0.01% | 779 |
|
|
2026
Q1 | $1.41M | Sell |
7,185
-102
| -1% | -$19.8K | ﹤0.01% | 759 |
|
|
2025
Q4 | $1.26M | Buy |
7,287
+71
| +1% | +$12.9K | ﹤0.01% | 779 |
|
|
2025
Q3 | $1.38M | Buy |
7,216
+89
| +1% | +$15.8K | ﹤0.01% | 743 |
|
|
2025
Q2 | $1.28M | Buy |
7,127
+46
| +0.6% | +$7.99K | ﹤0.01% | 750 |
|
|
2025
Q1 | $1.2M | Buy |
7,081
+150
| +2% | +$24.6K | ﹤0.01% | 734 |
|
|
2024
Q4 | $1.05M | Buy |
6,931
+358
| +5% | +$55.7K | ﹤0.01% | 795 |
|
|
2024
Q3 | $1.02M | Buy |
6,573
+93
| +1% | +$13.9K | ﹤0.01% | 781 |
|
|
2024
Q2 | $887K | Buy |
6,480
+331
| +5% | +$45.3K | ﹤0.01% | 802 |
|
|
2024
Q1 | $818K | Sell |
6,149
-280
| -4% | -$36.3K | ﹤0.01% | 828 |
|
|
2023
Q4 | $886K | Sell |
6,429
-22
| -0.3% | -$2.89K | ﹤0.01% | 797 |
|
|
2023
Q3 | $786K | Sell |
6,451
-397
| -6% | -$52.9K | ﹤0.01% | 797 |
|
|
2023
Q2 | $963K | Sell |
6,848
-431
| -6% | -$59.4K | ﹤0.01% | 758 |
|
|
2023
Q1 | $1.03M | Buy |
7,279
+718
| +11% | +$103K | ﹤0.01% | 750 |
|
|
2022
Q4 | $1.03M | Sell |
6,561
-128
| -2% | -$18.4K | ﹤0.01% | 744 |
|
|
2022
Q3 | $821K | Buy |
6,689
+79
| +1% | +$10.4K | ﹤0.01% | 747 |
|
|
2022
Q2 | $879K | Sell |
6,610
-206
| -3% | -$28.1K | ﹤0.01% | 726 |
|
|
2022
Q1 | $933K | Sell |
6,816
-983
| -13% | -$137K | ﹤0.01% | 728 |
|
|
2021
Q4 | $1.35M | Buy |
7,799
+661
| +9% | +$101K | ﹤0.01% | 672 |
|
|
2021
Q3 | $1.04M | Sell |
7,138
-114
| -2% | -$16.7K | ﹤0.01% | 687 |
|
|
2021
Q2 | $957K | Buy |
7,252
+894
| +14% | +$117K | ﹤0.01% | 711 |
|
|
2021
Q1 | $816K | Sell |
6,358
-333
| -5% | -$41K | ﹤0.01% | 745 |
|
|
2020
Q4 | $798K | Buy |
6,691
+81
| +1% | +$9.88K | ﹤0.01% | 701 |
|
|
2020
Q3 | $757K | Buy |
6,610
+69
| +1% | +$8.15K | ﹤0.01% | 658 |
|
|
2020
Q2 | $746K | Buy |
6,541
+674
| +11% | +$71.5K | ﹤0.01% | 657 |
|
|
2020
Q1 | $472K | Sell |
5,867
-17
| -0.3% | -$1.76K | ﹤0.01% | 705 |
|
|
2019
Q4 | $629K | Sell |
5,884
-708
| -11% | -$73.8K | ﹤0.01% | 720 |
|
|
2019
Q3 | $705K | Buy |
6,592
+896
| +16% | +$92K | ﹤0.01% | 684 |
|
|
2019
Q2 | $580K | Sell |
5,696
-1,964
| -26% | -$189K | ﹤0.01% | 727 |
|
|
2019
Q1 | $689K | Sell |
7,660
-21
| -0.3% | -$1.82K | ﹤0.01% | 901 |
|
|
2018
Q4 | $640K | Buy |
7,681
+89
| +1% | +$8.34K | ﹤0.01% | 870 |
|
|
2018
Q3 | $819K | Buy |
7,592
+1,429
| +23% | +$157K | ﹤0.01% | 861 |
|
|
2018
Q2 | $678K | Sell |
6,163
-46
| -0.7% | -$4.79K | ﹤0.01% | 896 |
|
|
2018
Q1 | $623K | Sell |
6,209
-328
| -5% | -$33.6K | ﹤0.01% | 773 |
|
|
2017
Q4 | $644K | Buy |
6,537
+40
| +0.6% | +$3.79K | ﹤0.01% | 800 |
|
|
2017
Q3 | $609K | Buy |
6,497
+12
| +0.2% | +$1.27K | ﹤0.01% | 792 |
|
|
2017
Q2 | $720K | Sell |
6,485
-125
| -2% | -$13.2K | ﹤0.01% | 753 |
|
|
2017
Q1 | $649K | Buy |
6,610
+291
| +5% | +$27.7K | ﹤0.01% | 742 |
|
|
2016
Q4 | $581K | Buy |
6,319
+106
| +2% | +$9.14K | ﹤0.01% | 758 |
|
|
2016
Q3 | $527K | Buy |
6,213
+250
| +4% | +$21K | ﹤0.01% | 755 |
|
|
2016
Q2 | $485K | Buy |
5,963
+1,920
| +47% | +$146K | ﹤0.01% | 752 |
|
|
2016
Q1 | $289K | Buy |
+4,043
| New | +$271K | ﹤0.01% | 837 |
|
|
2014
Q1 | – | Sell |
-1,065
| Closed | -$57K | – | 990 |
|
|
2013
Q4 | $57K | Buy |
+1,065
| New | +$63.2K | ﹤0.01% | 894 |
|
Other funds holding DGX
EIG
Brown Advisory's DGX Position: Q2 2026 in Review
Brown Advisory increased its Quest Diagnostics (DGX) stake by 5% in Q2 2026, buying an estimated $69.9K and bringing the position to 7,541 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #779.
Brown Advisory first reported a position in DGX in Q4 2013 and has held it in 43 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Brown Advisory held 7,541 shares of Quest Diagnostics worth $1.6M as of Q2 2026.
- Brown Advisory bought 356 Quest Diagnostics shares in Q2 2026, an estimated $69.9K.
- Quest Diagnostics made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #779 holding.
- Brown Advisory first reported a position in Quest Diagnostics in Q4 2013 and has held it in 43 quarters since.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.